Fasturtec

Fasturtec

rasburicase

Manufacturer:

sanofi-aventis
Concise Prescribing Info
Contents
Rasburicase

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Indications/Uses
Treatment & prophylaxis of acute hyperuricaemia to prevent acute renal failure in patients w/ haematological malignancy w/ high tumour burden & at risk of rapid tumour lysis or shrinkage at chemotherapy initiation.
Dosage/Direction for Use
IV Recommended dose: 0.2 mg/kg daily as a once daily 30 min infusion. Treatment duration: May be up to 7 days.
Contraindications
Hypersensitivity to rasburicase or uricases. G6PD deficiency & other cellular metabolic disorders known to cause haemolytic anaemia.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Supportive Care Therapy / Antidotes & Detoxifying Agents
ATC Classification
V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Presentation/Packing
Form
Fasturtec soln for infusion 1.5 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in